Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies.
about
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patientsMycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.Treatment of five haemodynamically stable dogs with immune-mediated thrombocytopenia using mycophenolate mofetil as single agent.Circadian variation of cytotoxicity and genotoxicity induced by an immunosuppressive agent "Mycophenolate Mofetil" in rats.Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantationThe emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room.Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases.Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoringUGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.The use of mycophenolate mofetil in liver transplant recipients.Mycophenolate mofetil in solid-organ transplantation.Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Review of the immunosuppressant enteric-coated mycophenolate sodium.Mycophenolic acid pharmacokinetics and related outcomes early after renal transplantPharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.Pharmacokinetic principles of immunosuppressive drugs.Time-dependent clearance of mycophenolic acid in renal transplant recipientsEffects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritisFree mycophenolic acid determination in human plasma ultrafiltrate by a validated liquid chromatography-tandem mass spectrometry method.UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipientsIndividualization of mycophenolate mofetil dose in renal transplant recipients.Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients.Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability.Mycophenolate mofetil in liver transplantation--is monotherapy safe?Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?A perspective on efflux transport proteins in the liverInosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune diseasePharmacokinetic evaluation of mycophenolate mofetil for pemphigus.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
P2860
Q28272907-BFEF357B-EE2C-4D25-BF32-91DB6227373FQ33370034-AA01F2B5-F8A5-479E-A4C6-4D88376C5E07Q33413713-A612D4ED-4340-41AF-A733-FDD1277FA2B7Q33434301-08B59FEA-7591-4A71-BD89-BED90CDA4F7CQ33696568-9229E97B-BA45-4C9B-8DD0-C2AB3A8A425DQ33764989-A51C1097-AB2D-4D43-841D-D5F60983B6DBQ33852812-63AA0253-1237-4071-8923-BAE0C8B5CBA6Q33944794-D1ED821A-03EF-4642-8208-4BBFF93C068CQ34152549-D18453C8-F69E-43EB-BA33-6C714EBB9795Q34180482-D5C9CAB6-511A-4688-93C1-BE39BC08FBAFQ34536203-85FF5DCB-31F7-410A-BD43-46F2CED79D03Q34611858-EDD14E64-9934-41AA-91A9-E572021FAFD1Q34635584-634B8711-E577-4ABF-B779-985B5F8D209BQ34858098-5C7F3745-4732-4912-807C-C8035935DC28Q34947658-22877171-CC89-4106-BEA4-DD2BA96F1847Q34984788-20115F5F-19B1-43B0-B6B2-B038BC71E10AQ35574966-B4C617CC-37C6-46E3-BF79-4E47469012CBQ35594016-F17FDB29-0530-40BC-BFE8-00CD2989E4D2Q35619332-C53F80E3-37FF-4BE9-832D-5B553923C56FQ35784063-21D956EF-9261-4C3C-9BC5-2F6F36D987F9Q35826828-372CA924-3157-4B6D-8506-0C6FC0E3B1BAQ35848175-2D11A9C8-2ED6-4B6A-95F5-3CBB6DA5A309Q36006086-0906ECB7-E68C-416A-815C-4EEFEA685F2FQ36024478-CE0ABEAD-4EE5-4BE2-A8D8-F891D796823EQ36025085-3B8F8D68-676C-4059-8B22-C31F3DAE4253Q36111207-F555304C-85F3-424E-83CF-12E7CCC26D39Q36243640-1C909447-5C52-4F27-820E-4491BDF9AA93Q36314080-0B5D6085-9582-4070-BB5E-349D996E1B29Q36400272-4E7A9451-6BF0-4206-8802-1C3051BB2E41Q36407345-16F9470F-1168-4C3C-AF85-D03E86FE3827Q36482172-71C9AEC1-F8AF-43B3-AA03-2EABC8E8621DQ36544988-908E2277-6984-4C48-84B7-C0DF5AD65D4BQ36652058-55FAF25C-6A82-46FF-B429-3D9238E023E5Q36788423-C6FC6924-557D-4F81-A402-111342BAF415Q37050337-139CBF68-30AD-483A-878C-1602B791E6CDQ37161962-0BD81E48-D6B0-4C1A-BB28-609BBFA2CF26Q37201939-406BA7E6-FAB0-4B5E-99D2-28C5C94412C2Q37818144-F74E2AA2-22FC-40EF-9BFD-CF281D023429Q37824708-E0FF332B-5DC8-49DB-9313-E52B3183C252Q38087925-95E41243-8557-452B-B3BB-9232E381B4FA
P2860
Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mycophenolic acid pharmacodyna ...... ational monitoring strategies.
@ast
Mycophenolic acid pharmacodyna ...... ational monitoring strategies.
@en
type
label
Mycophenolic acid pharmacodyna ...... ational monitoring strategies.
@ast
Mycophenolic acid pharmacodyna ...... ational monitoring strategies.
@en
prefLabel
Mycophenolic acid pharmacodyna ...... ational monitoring strategies.
@ast
Mycophenolic acid pharmacodyna ...... ational monitoring strategies.
@en
P2093
P2860
P1476
Mycophenolic acid pharmacodyna ...... ational monitoring strategies.
@en
P2093
Kenneth L Brayman
Lee Goldberg
Leslie M Shaw
Magdalena Korecka
Raman Venkataramanan
P2860
P304
P356
10.1034/J.1600-6143.2003.00079.X
P407
P577
2003-05-01T00:00:00Z